AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04281550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Think Drink
Description: The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
Study NCT03475615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2, d1, q3w
Study NCT03475615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, d1, q3w
Study NCT01379781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for PPD
Description: We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
Study NCT02546388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTATATE
Study NCT02951000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platysma suture
Study NCT02951000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no platysma suture
Study NCT03863080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RVT-1401
Description: Subcutaneous administration of RVT-1401
Study NCT03863080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401
Description: Subcutaneous administration of RVT-1401
Study NCT03863080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of Placebo
Study NCT03054246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of chewing side preference
Description: The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle.
Study NCT01080079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 4% w/w Terbinafine Hydrochloride Gel
Study NCT01080079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Purified Water
Description: Purified Water
Study NCT01355952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: 600mg three times per day (1800mg total) daily for 10 weeks
Study NCT03656289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68Mg Implant
Description: Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
Study NCT00119184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External cephalic version
Description: 7.5 mg bupivacaine intrathecally
Study NCT00119184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External cephalic version
Description: 7.5 mg bupivacaine intrathecally
Study NCT00119184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: spinal anesthesia
Study NCT01580163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JITAI Combined with psychological intervention
Description: tablet，Each tablet weight 0.4g
Study NCT01580163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Oral Solution，1mg/ml
Study NCT01580163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine JITAI
Description: tablet，Each tablet weight 0.4g
Study NCT00921375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TULY
Description: TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
Study NCT04881994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
Study NCT03095859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation.
Description: Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
Study NCT03095859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation.
Description: Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
Study NCT00525161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
Study NCT00710697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picoplatin
Description: IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01213680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer (iron isomaltoside 1000)
Description: 1000 mg iron isomaltoside administered as a infusion over 15 minutes
Study NCT01213680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer
Description: 500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
Study NCT02917096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HCT
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02917096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03475615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 40mg/m2 ip，d1、8 ,q3w
Study NCT03475615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
Description: 40mg/m2 Bid po，d1-14,q3w
Study NCT03475615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
Description: 40mg/m2 Bid po，d1-14,q3w
Study NCT06195254 — intervention group
Intervention type: RADIATION
Intervention: Stereotactic body radiotherapy (SBRT)
Description: All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions.
Study NCT06195254 — intervention group
Intervention type: DRUG
Intervention: PD-1 blocking antibody
Description: All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
Study NCT04581668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurally adjusted ventilatory assist first
Description: Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode
Study NCT04581668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional ventilation first
Description: Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
Study NCT00624143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORAL VORICONAZOLE and IV Amphotericin B
Description: Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
Study NCT05342909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5x a week BFR training group
Description: This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
Study NCT05342909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2x a week BFR training group
Description: This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
Study NCT01990560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
Study NCT01236339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
Description: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
Study NCT01236339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVP
Description: Large Volume Paracentesis
Study NCT01236339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol
Study NCT02054741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete geriatric assessment
Study NCT02054741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02054741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03390374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin Oral
Description: Nystatin oral suspension
Study NCT04196101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Four tablets daily for 5 days
Study NCT04196101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets daily for 5 days
Study NCT00784693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 15 mg IV single dose
Study NCT00784693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV single dose
Study NCT04621591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saneso 360° gastroscope
Description: Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
Study NCT01501760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
Study NCT01501760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
Study NCT01362257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 1 - IV dose of GSK573719
Description: single dose of 65µg
Study NCT01362257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 2 - Oral dose of GSK573719
Description: single dose of 1000µg
Study NCT03656523 — intervention group
Intervention type: OTHER
Intervention: Acute coronary syndrome and PCI and AF
Description: Patient with ACS and ACS treated with PCI
Study NCT03154060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle Libre Flash Glucose Monitoring sensors
Description: Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
Study NCT00220753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQAir Allergen 100 Air cleaners
Description: Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
Study NCT00220753 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IQAir Allergen 100 Air cleaners
Description: Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
Study NCT01994668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: A single intravenous administration of 2 mg lorazepam over 1 minute
Study NCT01994668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravenous administration of 0.9% saline over 1 minute
Study NCT02080741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample of 12 ml
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02917096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT02917096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT00750438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propionate ester
Description: The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
Study NCT00750438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
Study NCT00750438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
Study NCT03213691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03213691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT03213691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT00928408 — intervention group
Intervention type: DRUG
Intervention: Cinacalcet
Study NCT06409546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocopherol and pentoxifilline topical gel
Description: Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
Study NCT06409546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
Study NCT04016623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-day toric test contact lens
Description: somofilcon A 1-day toric test contact lens
Study NCT04016623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-day toric test contact lens
Description: somofilcon A 1-day toric test contact lens
Study NCT04016623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-day toric control contact lens
Description: somofilcon A 1-day toric control contact lens
Study NCT04016623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-day toric control contact lens
Description: somofilcon A 1-day toric control contact lens
Study NCT00174187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
Study NCT01703767 — intervention group
Intervention type: BEHAVIORAL
Intervention: Provider Education Workshop
Description: Educational resources for physicians regarding the needs of GW1V patients.
Study NCT04633265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-I Mapping of Atrial Fibrillation
Description: Catheter ablation of Atrial Fibrillation guided by ECG-I
Study NCT04235608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled sedation with sevoflurane
Description: Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
Study NCT04235608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous sedation with propofol
Description: intravenous sedation with propofol, as already routinely used in participating ICUs.
Study NCT01063751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tritanium® Primary Acetabular Shell
Description: Tritanium® Primary Acetabular Shell in total hip replacement.
Study NCT04489173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Description: Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days.
Study NCT03173248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: Tablets administered orally
Study NCT03173248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study NCT03173248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered SC or IV
Study NCT03173248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered SC or IV
Study NCT02828826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone coaching
Study NCT02023463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02023463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: Given SC
Study NCT02023463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Given IM or SC
Study NCT02023463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo image-guided radiation therapy
Study NCT02386475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
Study NCT02386475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
Study NCT02386475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sinemet plus
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.